← Back to Patent Explorer
US5652355A Expired / Lapsed US ⏱️ 0.0 years remaining

Hybrid oligonucleotide phosphorothioates

Assignee: WORESTER FOUNDATION FOR BIOMEDICAL RESEARCH Inc
•
Filing: 1992-07-23
•
Granted: 1997-07-29
•
Expires: 2012-07-23
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention provides hybrid oligonucleotides having phosphorothioate or phosphorodithioate internucleotide linkages, and both deoxyribonucleosides and ribonueleosides or 2'-substituted ribonucleosides. Such hybrid oligonucleotides have superior properties of duplex formation with RNA, nuclease resistance, and RNase H activation.

Inventors

  • 👤 Valeri Metelev
  • 👤 Sudhir Agrawal

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-04 22:36
CPC Classifications
C; C12; C12N; C12N15/00; C12N15/09; C12N15/11; C12N15/113; A; A61; A61P; A61P29/00; A61P31/00; A61P31/04; A61P31/12; A61P31/14; A61P31/18; A61P33/00; A61P33/02; A61P35/00; A61P9/00; A61P9/10; A61P9/12; C07; C07H; C07H21/00; C12N15/1131; C12N15/1132; C12N2310/00; C12N2310/30; C12N2310/31; C12N2310/313; C12N2310/315; C12N2310/32; C12N2310/321; C12N2310/34; C12N2310/341; C12N2310/346; C12N2310/35; C12N2310/352; C12N2310/3521

Claims Analysis

Total Claims: 13
Claim 1
Independent Claim 50 words
A hybrid oligonucleotide that is complementary to a target RNA, the hybrid oligonucleotide consisting of phosphorothioate nucleotides and comprising a segment of at least two contiguous 2'-O-methyl-substituted ribonucleotides as the terminal two nucleotides at each end of the oligonucleotide, and further comprising a segment of at least three contiguous deoxyribonucleotides.
Claim 2
Dependent Claim 50 words
A hybrid oligonucleotide that is complementary to a target RNA, the hybrid oligonucleotide consisting of phosphorothioate nucleotides and comprising a segment of at least two contiguous 2'-O-methyl-substituted ribonucleotides as the terminal two nucleotides at each end of the oligonucleotide, and further comprising a segment of at least three contiguous deoxyribonucleotides.
Claim 3
Dependent Claim 21 words
A hybrid oligonucleotide according to claim 1, wherein the deoxyribonucleotide is present in a segment of at least four contiguous deoxyribonucleotides.
Claim 4
Dependent Claim 14 words
An oligonucleotide according to claim 1 comprising from about 6 to about 50 nucleotides.
Claim 5
Dependent Claim 14 words
An oligonucleotide according to claim 2 comprising from about 6 to about 50 nucleotides.
Claim 6
Dependent Claim 16 words
An oligonucleotide according to claim 1 wherein the target RNA is a RNA from a virus.
Claim 7
Dependent Claim 16 words
An oligonucleotide according to claim 2 wherein the target RNA is a RNA from a virus.
Claim 8
Dependent Claim 16 words
An oligonucleotide according to claim 3 wherein the target RNA is a RNA from a virus.
Claim 9
Dependent Claim 16 words
An oligonucleotide according to claim 4 wherein the target RNA is a RNA from a virus.
Claim 10
Dependent Claim 15 words
An oligonucleotide according to claim 1 wherein the target RNA is a RNA from HIV.
Claim 11
Dependent Claim 15 words
An oligonucleotide according to claim 2 wherein the target RNA is a RNA from HIV.
Claim 12
Dependent Claim 15 words
An oligonucleotide according to claim 3 wherein the target RNA is a RNA from HIV.
Claim 13
Dependent Claim 15 words
An oligonucleotide according to claim 4 wherein the target RNA is a RNA from HIV.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2000-07-28 2001-01-27 2001-07-29 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2004-07-28 2005-01-27 2005-07-29 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2008-07-28 2009-01-27 2009-07-29 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag